tivozanib 1.34 MG Oral Capsule

RxCUI
2534247
RxNorm name
tivozanib 1.34 MG Oral Capsule
Display name
tivozanib 1.34 MG Oral Capsule
Full name
tivozanib 1.34 MG Oral Capsule
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:24

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FOTIVDATIVOZANIBAVEO Pharmaceuticals, Inc.de77155c-ecf2-4f15-9758-21d271449d832026-09-15Warnings, Adverse reactionsExact identifier
rxcui: 2534247

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
de77155c-ecf2-4f15-9758-21d271449d83tivozanib 1.34 MG Oral Capsule [PSN] · tivozanib 1.34 MG Oral Capsule [SCD] · tivozanib (as tivozanib hydrochloride 1.5 MG) 1.34 MG Oral Capsule [SY]313These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 202120251001